Objective: We aimed to evaluate the effectiveness of single, two or three additive doses of premixed insulin lispro %25 or three doses of premixed insulin lispro %50 to existing OAD treatments, on HbA1C levels in Type II Diabetics with poor glycemic control. Materials and Methods: 112 patients with Type II DM with HbA1c levels >%7, despite using one or more OAD, and 29 patients with HbA1c levels >%7, despite using premixed insulin lispro %25 and %75 insulin lispro protamin suspension twice a day, and/or one or more OAD, were included in our study. Injectable premixed insulin lispro %25 twice a day was prescribed to patients, whose blood glucose levels didnt regulate at the end of the 3rd month with additive premixed insulin lispro %25 to their existing OAD treatment. At the end of the 6th month, the patients with still unregulated blood glucose levels had premixed insulin lispro %25 or premixed insulin lispro %50 three times a day. The HbA1c levels were checked at 3, 6, and 9th months and compared with the basal levels. Results: %25 of the patients using premixed insulin lispro %25 once a day, 47.5% of the patients using it twice a day, and 77% of the patients using premixed insulin lispro %25 three times a day reached to the HbA1c
Key words: Glycemic control, postprandial hyperglycemia, premixed insulin lispro %25, premixed insulin lispro %50, HbA1c
|